Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Cash from Operations (2016 - 2025)

BioCorRx's Cash from Operations history spans 16 years, with the latest figure at 634447.0 for Q3 2025.

  • For Q3 2025, Cash from Operations fell 77.45% year-over-year to 634447.0; the TTM value through Sep 2025 reached 1697739.0, down 22.76%, while the annual FY2024 figure was 1096254.0, 40.85% up from the prior year.
  • Cash from Operations for Q3 2025 was 634447.0 at BioCorRx, down from 126499.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 126499.0 in Q2 2025 and bottomed at 1338229.0 in Q2 2021.
  • The 5-year median for Cash from Operations is 449576.0 (2022), against an average of 525238.74.
  • The largest annual shift saw Cash from Operations plummeted 147.93% in 2021 before it skyrocketed 73.72% in 2022.
  • A 5-year view of Cash from Operations shows it stood at 647624.0 in 2021, then surged by 30.58% to 449576.0 in 2022, then dropped by 18.74% to 533836.0 in 2023, then surged by 53.7% to 247170.0 in 2024, then crashed by 156.68% to 634447.0 in 2025.
  • Per Business Quant, the three most recent readings for BICX's Cash from Operations are 634447.0 (Q3 2025), 126499.0 (Q2 2025), and 689623.0 (Q1 2025).